Skip to main content
Caplight Logo









DalCor Pharmaceuticals

DalCor Pharmaceuticals

Private
MontrealHealthcare & Life Scienceshttps://dalcorpharma.com/

Last Round

Seed Round

Aug 28, 2026

Total Funding Raised

$230M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

DalCor Pharmaceuticals is a biopharmaceutical company that develops dalcetrapib, a pharmacogenetic precision medicine for cardiovascular disease that specifically targets patients with the ADCY9 AA genotype.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

precision medicinepharmacogeneticscompanion diagnosticacute coronary syndromeACScardiovascular diseasebiopharmaceuticalgenotyping assayclinical trialspersonalized medicinegenetic testingdrug developmentbiotechgenomic medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DalCor Pharmaceuticals Comparables

Compare DalCor Pharmaceuticals with similar companies based on industry and business-model similarity.

DalCor Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cardurion Pharmaceuticals
71%
Abcentra
68%
Novo Nordisk
67%

DalCor Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundAug 28, 2026
Series DSep 13, 2023
Series BApr 19, 2016
Series ANov 1, 2015

Key People

Founding team and executive leadership

Fouzia Laghrissi-Thode

Chief Executive Officer

Executive Team

CA Michael Dixon

Chief Financial Officer

Executive Team

DalCor Pharmaceuticals Investors

Notable investors and investment history

DalCor Pharmaceuticals investors
InvestorRounds
Investissement QuébecSeries D
CTI Life Sciences FundSeries D, Series B
Investissement QuébecSeries D
Fonds de solidarité FTQSeries D, Series B
Caisse de dépôt et placement du QuébecSeries B
Caisse de dépôt et placement du QuébecSeries B
Sanderling VenturesSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 28, 2026

    $7M round raised

DalCor Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

DalCor Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about DalCor Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersMontreal
Employee Range16
Year Founded2015
Last FundingAug 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?